Sirona Dental Systems (SIRO) 10-Q 7 Aug 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jun. 30, 2015	Jul. 31, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Document period end date	Jun. 30, 2015
Amendment flag	false
Current fiscal year end date	--09-30
Entity central index key	1,014,507
Entity current reporting status	Yes
Entity filer category	Large Accelerated Filer
Entity registrant name	SIRONA DENTAL SYSTEMS, INC.
Entity voluntary filers	No
Trading Symbol	SIRO
Entity well known seasoned issuer	Yes
Entity common stock shares outstanding		55,856,681
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
REVENUE	$ 306.1	$ 299.7	$ 856.4	$ 881.1
Cost of goods sold	(131.5)	(132.1)	(375.1)	(399.3)
GROSS PROFIT	174.6	167.6	481.3	481.8
Selling, general and administrative expense	(84)	(88.1)	(253.9)	(263.3)
Research and development expense	(12.9)	(16.6)	(41.9)	(48.1)
Net other operating income (loss)	2.7	4.4	7.7	9.4
OPERATING INCOME	80.4	67.3	193.2	179.8
Gain (loss) on foreign currency transactions	(5.1)	2.2	(6.4)	1.6
Gain (loss) on derivative instruments	4	(0.5)	1.7	(1.4)
Interest income (expense)	(1)	(0.7)	(2.7)	(2.4)
Other income (expense)	(1.1)	(0.6)	(0.6)	(1.5)
INCOME BEFORE TAXES	77.2	67.7	185.2	176.1
Income tax benefit (expense)	(17.8)	(15.9)	(42.6)	(41.4)
NET INCOME	59.4	51.8	142.6	134.7
Net (income) loss attributable to noncontrolling interests	(0.6)	(0.3)	(1.8)	(1.7)
NET INCOME ATTRIBUTABLE TO SIRONA DENTAL SYSTEMS, INC.	$ 58.8	$ 51.5	$ 140.8	$ 133
INCOME PER SHARE (attributable to Sirona Dental Systems, Inc. common shareholders):
Basic	$ 1.06	$ 0.93	$ 2.53	$ 2.41
Diluted	$ 1.04	$ 0.92	$ 2.5	$ 2.37
Weighted average shares - basic	55,706,017	55,362,620	55,568,488	55,251,782
Weighted average shares - diluted	56,396,820	56,238,076	56,358,943	56,201,358

CONSOLIDATED STATEMENT OF COMPR

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)
NET INCOME	$ 59.4	$ 51.8	$ 142.6	$ 134.7
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX
Cumulative translation adjustment	35.4	(9.9)	(110.1)	7.9
Derivative financial hedging instruments	0.1	0.1	0.2	0.3
Unrecognized elements of pension cost	0.3	(0.2)	(2)	(0.1)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	35.8	(10)	(111.9)	8.1
TOTAL COMPREHENSIVE INCOME (LOSS)	95.2	41.8	30.7	142.8
Comprehensive (income) loss attributable to noncontrolling interests	(0.7)	(0.2)	(1.6)	(1.7)
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO SIRONA DENTAL SYSTEMS, INC. SHAREHOLDERS	$ 94.5	$ 41.6	$ 29.1	$ 141.1

CONSOLIDATED BALANCE SHEETS (UN

CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Jun. 30, 2015	Sep. 30, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 422.6	$ 382.8
Restricted cash	0.7	0.8
Accounts receivable, net of allowance for doubtful accounts of $2.3 and $2.4, respectively	184	115.6
Inventories, net	132.4	123.4
Deferred tax assets	24.5	29.7
Prepaid expenses and other current assets	30.1	26.8
Income tax receivable	16.2	8
TOTAL CURRENT ASSETS	810.5	687.1
Property, plant and equipment, net of accumulated depreciation of $195.3 and $171.3, respectively	207.6	221
Goodwill	587.5	629.3
Restricted cash	0.4	0
Intangible assets, net of accumulated amortization of $490.0 and $511.3, respectively	213.9	252.8
Other non-current assets	4.8	5.3
Deferred tax assets	14.5	15.5
TOTAL ASSETS	1,839.2	1,811
CURRENT LIABILITIES
Trade accounts payable	71.5	59.9
Short-term financial liabilities	23.4	1.5
Income taxes payable	7.7	6.1
Deferred tax liabilities	3.1	2.2
Accrued liabilities and deferred income	188.4	167.6
TOTAL CURRENT LIABILITIES	294.1	237.3
Long-term financial liabilities	57	78
Deferred tax liabilities	97.5	111.8
Other non-current liabilities	23.1	25.1
Pension related provisions	63.4	71.7
Deferred income	17.4	25.9
TOTAL LIABILITIES	552.5	549.8
SHAREHOLDERS` EQUITY
Preferred stock ($0.01 par value; 5,000,000 shares authorized; none issued and outstanding)	0	0
Common stock ($0.01 par value; 95,000,000 shares authorized; 58,323,771 shares issued; 55,852,272 shares outstanding at Jun. 30, 2015; 57,776,336 shares issued; 55,364,617 shares outstanding at Sept. 30, 2014)	0.6	0.6
Additional paid-in capital	699.3	697.9
Treasury stock, at cost, 2,471,499 shares held at cost at Jun. 30, 2015; 2,411,719 shares held at cost at Sept. 30, 2014	(132)	(126.8)
Retained earnings	900.7	759.9
Accumulated other comprehensive income (loss)	(184.5)	(72.8)
TOTAL SIRONA DENTAL SYSTEMS, INC. SHAREHOLDERS` EQUITY	1,284.1	1,258.8
NONCONTROLLING INTERESTS	2.6	2.4
TOTAL SHAREHOLDERS` EQUITY	1,286.7	1,261.2
TOTAL LIABILITIES & SHAREHOLDERS` EQUITY	$ 1,839.2	$ 1,811

CONSOLIDATED BALANCE SHEETS (U5

CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentheticals) - USD ($) $ in Millions	Jun. 30, 2015	Sep. 30, 2014
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
Allowance for doubtful accounts	$ 2.3	$ 2.4
Accumulated depreciation and amortization	195.3	171.3
Finite-Lived Intangible Assets, Accumulated amortization	$ 490	$ 511.3
Preferred stock par value per share	$ 0.01	$ 0.01
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value per share	$ 0.01	$ 0.01
Common stock shares authorized	95,000,000	95,000,000
Common stock shares issued	58,323,771	57,776,336
Common stock shares outstanding	55,852,272	55,364,617
Treasury stock shares	2,471,499	2,411,719

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
OPERATING ACTIVITIES
NET INCOME	$ 142.6	$ 134.7
ADJUSTMENTS TO RECONCILE NET INCOME TO NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
Depreciation and amortization	52	56.5
(Gain) loss on derivative instruments and foreign currency transactions	4.7	(0.2)
Deferred income taxes	0.6	(9.6)
Share-based compensation expense	10.1	8.6
Other adjustments	0.4	(1.5)
TOTAL ADJUSTMENTS TO RECONCILE NET INCOME TO OPERATING CASH FLOWS	67.8	53.8
CHANGES IN ASSETS AND LIABILITIES
Accounts receivable	(79)	(26.4)
Inventories	(22.9)	(24.8)
Trade accounts payable	16.9	(9.1)
Other current and non-current assets	(7.2)	5.3
Other current and non-current liabilities	19.8	(2.1)
Current income taxes	(6.5)	(0.9)
EFFECT OF CHANGES IN ASSETS AND LIABILITIES ON OPERATING CASH FLOWS	(78.9)	(58)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	131.5	130.5
INVESTING ACTIVITIES
Investment in property, plant and equipment	(38.6)	(74.5)
Proceeds from sale of property, plant and equipment	0.5	0.6
Purchase of intangible assets	(0.2)	(0.1)
Acquisition of businesses, net of cash acquired	(18.5)	0
Sale of businesses, net of cash sold	0	11.5
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	(56.8)	(62.5)
FINANCING ACTIVITIES
Purchase of treasury stock	(5.2)	(14.8)
Dividend distributions to noncontrolling interest	0	(1.5)
Common shares issued under share based compensation plans	3.8	6.7
Tax effect of common shares issued under share based compensation plans	(14.4)	(3.5)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	(15.8)	(13.1)
CHANGE IN CASH AND CASH EQUIVALENTS	58.9	54.9
Effect of exchange rate change on cash and cash equivalents	(19.1)	0.4
Cash and cash equivalents at beginning of period	382.8	241.7
CASH AND CASH EQUIVALENTS AT END OF PERIOD	422.6	297
SUPPLEMENTAL INFORMATION
Interest paid	1.6	2.3
Interest capitalized	0.2	0.3
Income taxes paid	$ 32.2	$ 46.6

General

General	9 Months Ended
	Jun. 30, 2015
General [Abstract]
General	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (condensed) 1 GENERAL THE COMPANY AND ITS O PERATIONS Sirona Dental Systems, Inc. (“Sirona,” the “Company,” “we,” “us,” and “our” refer to Sirona Dental Systems, Inc. and its consolidated subsidiaries) is the leading global manufacturer o f high-quality, technologically- advanced dental equipment, and is focuse d on developing, manufacturing , and marketing innovative systems and solutions for dentists around the world. We offer a broad range of products across all major segments of the dental technology mark et including CEREC and our other CAD/CAM systems, digita l intra oral and 2D and 3D panoramic imaging systems, treatment centers , and instruments. The Company acquired Schick Technologies, Inc. (“Schick”) in 2006, in a transaction accounted for as a reverse acquisition (the “Exchange”), further expanding our glo bal presence and product offerings and strengthening our research and development capabilities. Sirona has served equipment dealers and dentists worldwide for more than 130 years. The Company’s headqu arters is located in Long Island City, New York with its primary facility located in Bensheim , Germany, as well as other support, manufacturing, assembling, and sales and service facilities lo cated around the globe.

Basis Of Presentation And Summa

Basis Of Presentation And Summary Of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2015
Basis of Presentation and Significant Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with acco unting principles generally accepted in the United States (“U.S. GAAP”). All amounts are reported in millions of U.S. Dollars ($), except per share amounts or as otherwise disclosed. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Fiscal Year The Company’s fi scal year is October 1 to September 30. Principles of Consolidation The consolidated financial statements include, after eliminating inter-company transactions and balances, the accounts of Sirona Dental Systems, Inc. and its subsidiaries. Use of Estimat es Preparation of the interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions related to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as at th e reporting date and the reported amounts of revenues and expenses for the interim period. Actual results could differ from those estimates. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information not misleading. The year-end consolidated financial data was derived from the audited c onsolidated financial statements, but does not include all disclosures required by U.S. GAAP. These condensed c onsolidated financial statements should be read in conjunction with the Consolidated Financial Statements and the Notes thereto included in the C ompany’s Annual Report on Form 10-K for the fisc al year ended September 30, 2014 . In the opinion of management, all adjustments considered necessary to present fairly the Company’s f inancial position as of June 30, 2015 , and the results of operations and cash flows for the nine months ended June 30, 2015 and 2014 , respectively, as applicable to interim periods have been made. The results of operations for the nine months ended June 30, 2015 are not necessarily indicative of the operating results for the full fiscal year or future periods. Foreign Currency The functional currency for foreign operations has been determined in all cases to be the local currency. Assets and liabilities of foreign subsidiaries are translated into U.S. Dollars using period-end exchange rates, while revenues and expenses are translated into U.S. Dollars using weighted average exchange rates for the period. Resulting adjustme nts are recorded in shareholders’ equity as a component of accumulated other comprehensive income . Gains or losses resulting from transactions in other than the functional currency are reflected in the consolidated statements of income in Gain (loss) on fo reign currency transactions , except for intra-group transactions of a long-term nature, which are recorded in shareholders’ equity as a component of accumulated other comprehensive income .

Accounting Standards Issued

Accounting Standards Issued	9 Months Ended
	Jun. 30, 2015
Accounting standars issued [Abstract]
Accounting Standards Issued	3 ACCOUNTING STANDARDS ISSUED Changes to accounting principles generally accepted in the United States (“U.S. GAAP”) are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”). The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined to be either ( i ) not applicable, (ii) are expected to have a minimal impact on our consolidated financial statements, or (iii) their adoption had an immaterial impact on our consolidated financial statements. ADOPTED There were no ASUs adopted during the current period, which had a material impact on our consolidated financial statements. NOT YET ADOPTED In May 2015, the FASB issued ASU 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement , which provides guidance to customers about whether a cloud computing arrangement includes a software license. If such an arrangement contains a software license, the software license element of that arrangement should be accounted for consistent with the acquisition of other software licenses. If such an arrangement does not include a software license, the arrangement should be accounted for as a service contract. ASU 2015-05 is effective for public entities for fiscal years, and interim periods within those years, beginning after December 15, 2015, which corresponds to the Company’s fiscal year beginning October 1, 2016, wit h early adoption permitted. The new guidance permits either prospective or retrospective adoption. We are currently evaluating the potential impact of adoption on our consolidated financial statements and have not yet selected an adoption method. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs , which requires an entity to present such costs related to a recognized debt liability as a direct deduction from the carrying amount of that debt liability on the balan ce sheet rather than as an asset. ASU 2015-03 is effective for public entities for fiscal years, and interim periods within those years, beginning after December 15, 2015, which corresponds to the Company’s fiscal year beginning October 1, 2016, with early adoption permitted. Currently, we do not expect a material impact of adoption on our consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers , which provides updated guidance on revenue recognition principles that will supersede most current conceptual and industry-specific revenue recognition guidance and thus enhance comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. The key principle of this updated guidance is that entities should recognize revenue to depict the transfer of goods or services to customers at an amount reflecting the consideration to which an entity expects to be entitled in exchange for those goods or services. The new g uidance prescribes a five-step analysis of transactions to determine how and when to recognize revenue. In addition, the new guidance provides for capitalization of certain costs of obtaining or fulfilling a contract with a customer as well as enhanced dis closure requirements to enable a better understanding of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for public entities for fiscal years, and interim periods within those years, beginning after December 15, 2016. The new guidance permits the use of either a retrospective or cumulative effect transition method. In July 2015, the FASB approved a one-year deferral of the effective date to apply to fiscal years, and interim periods within those years, beginning after December 15, 2017, which corresponds to the Company’s fiscal y ear beginning October 1, 2018, with early adoption as of the original effective date permitted . We have not yet selected a transition method or adoption date and are evaluating the expected impact of adoption on our consolidated financial statements.

Business Acquisitions

Business Acquisitions	9 Months Ended
	Jun. 30, 2015
Business Acquisitions [Abstract]
Business Acquisitions	4 BUSINESS ACQUISITIONS On June 30, 2015, the Company acquired 100% of the outstanding shares of capital stock of a dental company. The results of its operations will be included in the consolidated financial statements from this date. The fair value of total consideration transferred for this acquisition totaled $18.6 million, consisting entirely of cash. The preliminary purchase price allocation resulted in goodwill acquired of $15.8 million. We expect to finalize the purchase price alloc ation for this acquisition by the end of the current fiscal year.

Employee Share-Based Compensati

Employee Share-Based Compensation	9 Months Ended
	Jun. 30, 2015
Employee Share-Based Compensation [Abstract]
Employee Share-Based Compensation	5 EMPLOYEE SHARE-BASED COMPENSATION ASC 718, Compensation – Stock Compensation , requires that all share based compensation arrangements, including grants of stock option awards to employees, be recognized based on the estimated fair value of the share-based payment award. EQUITY INCENTIVE PLAN Stock options, restricted stock share s, restricted stock units (“RSU”), and performance-based stock units (“PSU”) have been issued to employees, directors, and consultants under the Company’s 2006 Equity Incentive Plan (“200 6 Plan”). The 2006 Plan provided for granting in total up to 4,550,00 0 stock options, incentive stock, restricted stock shares , RSU’s, and PSU’s. The 2006 Plan received stockholder approval at the Company’s Annual Meeting of Stockholders held on February 27, 2007, and was amended on February 25, 2009. At the Company’s Annua l Meeting of Stockholders held on February 25, 2015, stockholders approved the Company’s new 2015 Long-Term Incentive Plan (“2015 Plan”) to replace the 2006 Plan. The 2015 Plan provides for granting in total up to 6,825,000 stock options, incentive shares, restricted stock shares, RSU’s, PSU’s, and other forms of equity-based awards to employees, directors, consultants, and advisers. Shares under the new 2015 Plan were first registered pursuant to a registration statement dated April 2, 2015, at which time these shares became available for grant and any remaining shares available under the 2006 Plan were nullified. To cover the exercise of options and vesting of RSU’s and PSU’s, the Company generally issues new shares from its authorized but unissued share p ool. As of June 30, 2015 , 6,804,157 shares were available for future grant und er the 2015 Plan. Restricted and Performance-Based Stock Units In the nine months ended June 30, 2015 , the Company granted 139,387 RSU’s and 37,004 PSU’s with an average value of $ 87.29 , representing the average of closing prices of the Company’s common stock at the grant dates. RSU’s generally vest in annual tranche s over a period of four to five years, while PSU’s generally vest after th ree years. The PSU’s were granted to certain Company executives an d vest three years from the date of the grant provid ed the Company achieves performance targets specified in the grant. RSU’s and PSU’s do not have voting rights or rights to dividends prior to vesting. The value of each RSU and PSU grant is determined by the closing price at the date of grant. Share-based compensation expense for the entire award is recognized straight-line over the service period of the last separately vesting tranche of the award. Stock Options In the nine months ended June 30, 2015 , the Company granted 160,262 stock o ptions with a weighted average exercise price of $ 86.00 and weighted average fair value of $ 22.90 a t the grant date. Grants generally vest over a period of f our to five year s. All grants expire ten years after the date of the grant. The fair v alue of options granted under the 2006 Plan was estimated using the Black-Scholes option pricing model using assumptions in the following table. The exercise price is equal to the fair m arket value of Sirona’s stock at the grant date. Expected volatility i s based on the Company’s historical stock price volatility. The risk-free rate is based on the U.S. Treasury yield curve in effect at the day of grant and has a term equal to the expecte d life of the option. The expected life represents the period of time the options are expected to be outstanding based on anticipated grantee behavior. The expected dividend yield is based on the Company’s history of not paying regular dividends in the pas t and the Company’s current intention not to pay dividends in the foreseeable future. Black-Scholes Assumptions Nine months ended Year ended June 30, September 30, 2015 2014 Expected Volatility 26.77% 33.27% Risk-free rate 1.58% 1.35% Expected term 5 years 5 years Expected dividends - - COMPENSATION COSTS The following table summarizes compensation expense charged to income for stock-based compensation and additional information for the three and nine months ended June 30, 2015 : Compensation Expense Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Compensation expense (1) $ 3.5 $ 2.8 $ 10.1 $ 9.2 (1) For the first nine months of fiscal years 2015 and 2014, this included a compensation charge of $0.5 million and $0.9 million, respectively, for share-based awards in connection with the CFO Transition. RESTRICTED AND PERFORMANCE-BASED STOCK UNIT ACTIVITY The following is a summary of Sirona’s RSU and PSU activity for the nine months ended June 30, 2015 : RSU and PSU Activity Nine months ended June 30, 2015 Restricted stock units Performance-based stock units Number of shares Weighted average market price at grant Number of shares Weighted average market price at grant Outstanding at beginning of period 491,781 $ 55.81 42,566 $ 66.63 Granted 139,387 87.63 37,004 86.00 Vested (182,170) 47.05 - - Forfeited (6,325) 62.48 - - Outstanding at end of period 442,673 $ 69.33 79,570 $ 75.64 STOCK OPTION ACTIVITY The following is a summary of Sirona’s stock option activity for the nine months ended June 30, 2015 : Stock Option Activity Nine months ended June 30, 2015 Number of options Weighted average exercise price Outstanding at beginning of period 1,560,592 $ 29.13 Granted 160,262 86.00 Exercised (711,489) 16.49 Forfeited (3,163) 51.59 Outstanding at end of period 1,006,202 $ 47.06 thereof vested and exercisable 591,925

Net Other Operating Income (Los

Net Other Operating Income (Loss)	9 Months Ended
	Jun. 30, 2015
Net Other Operating Income (Loss)[Abstract]
Net Other Operating Income	6 NET OTHER OPERATING INCOME (LOSS) The components of net other operating income (loss) for the periods under report are as follows: Net Other Operating Income (Loss) Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment $ 2.5 $ 2.5 $ 7.5 $ 7.5 Gain from patent infringement settlement (1) 0.1 - 0.1 - Other miscellaneous gain (loss) (2) 0.1 1.9 0.1 1.9 Net other operating income (loss) $ 2.7 $ 4.4 $ 7.7 $ 9.4 (1) The gain from patent infringement settlement for the three months ended June 30, 2015, represents amounts received for past lost profits in an out-of-court settlement of a patent defense suit in the normal course of business. (2) The other miscellaneous gain for the three months ended June 30, 2014, represents a gain on disposal of certain business assets. DEFERRED INCOME Effects of remeasurement of the Patterson Exclusivity Payment from U.S. Dollar to Euro are reflected in the statement of income. For the periods under report, these effects were as follows: Deferred Income (Patterson Exclusivity Payment) Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Foreign currency transaction gain (loss) resulting from the remeasurement of the deferred income related to the Patterson exclusivity payment $ 0.8 $ (0.3) $ (3.4) $ 0.5

Derivative Instruments and Hedg

Derivative Instruments and Hedging Strategies	9 Months Ended
	Jun. 30, 2015
Derivative Instruments And Hedging Strategies [Abstract]
Derivative Instruments and Hedging Strategies	7 DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES RISK S AND EXPOSURE Our operations are exposed to market risks from changes in foreign currency exchange rates and interest rates. In the normal course of business, these risks are managed through a variety of strategies, including the use of derivatives. Interest Rate Risk The Company is exposed to interest rate risk associated with fluctuations in the interest rates on its variable interest rate debt. In order to manage this risk, the Company enters into interest rate swap agreements, when appropriate, based upon market conditions. Foreign Currency Exposure Although the U.S. Dollar is Sirona’s reporting currency, it conducts its business in many currencies, and its local functional currency varies depend ing on the country of operation, which exposes the Company to market risk associated with foreign currency exchange rate movements. The Company hedge s certain foreign currency transaction exposure through foreign exchange forward contracts. CASH FL OW HEDGES Interest Rate The Company uses interest rate swaps to convert a portion of its debt's variable interest rate to a fixed interest rate . Interest rate swaps have been established for 100 % of the interest for the Facility A Term Loan under the Senio r Facilities Agreement until November 2016. The in terest rate swaps fix the LIBOR element of interest payable on 100 % of the principal amount of the Facility A Term Loan for defined three month interest periods ove r the entire term of the loan . The defined interest rates fixed for each three month interest perio d range from 1 . 270 % to 1.285 %. Settlement of the swaps is required on a quarterly basis. These swaps a re designated as hedging instruments under ASC 815. These instruments were immaterial for all per iods under report. The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments. Foreign Currency The Euro is the func tional currency for many of Sirona’s subsidiaries, including its primary sales and manufacturing operations in Germany. During the periods under review, the U.S. Dollar/Euro exchange rate fluctuated significantly, thereby impacting Sirona’s financial results. In order to hedge portions of the transactional exposure to fluctuations in exchange rates, based on forecasted and firmly-committed cash flows, Sirona enters into foreign exchange forward contracts (currently: USD, AUD, and JPY). These forward foreign currency contracts are intended to reduce short-te rm effects of changes in exchange rates. T he Company enters into forward contracts that are considered to be economic hedges but which are not considered hedging instruments under ASC 815. As of June 30, 2015 , these contracts had noti onal amounts totaling $ 36.1 million . These agreements are relatively short-term (generally not exceeding six months). The fair value carrying amount of the Company's derivat ive instruments at June 30, 2015 is described in Note 14 Fair Value Measurements. The following tables summarize the impact of gains and losses from the fair value changes of the Company’ s derivative instruments reported in our condensed consolidated statement s of income for the per iods under report: Derivatives Designated as Cash Flow Hedging Instruments Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Income For the three months ended For the nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Interest rate swap contracts $ 0.2 $ - $ 0.3 $ 0.2 Total $ 0.2 $ - $ 0.3 $ 0.2 Derivatives Not Designated as Hedging Instruments Amount of Gain (Loss) Recognized in Income on Derivative Instruments Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Affected Line Item in the Statement of Income Foreign exchange contracts $ 4.0 $ (0.5) $ 1.7 $ (1.4) Gain (loss) on derivative instruments, net

Income Taxes

Income Taxes	9 Months Ended
	Jun. 30, 2015
Income Taxes [Abstract]
Income Taxes	8 INCOME TAXES For the first nine months of fiscal year 2015 , an estimated effective tax rate of 23.0 % has been applied (prior year period: 23.5 % ) . The income tax provision for the first nine months ended June 30, 2015 , was $ 42.6 million (prior year period: $ 41.4 million) . The actual effective tax rate for fiscal year 2014 was 23.0 %. The Company's eff ective tax rate may vary significantly from perio d to period, and can be influenced by many factors. These factors include, but are not limited to, changes to statutory tax rates in the jurisdictions where the Company has operations, changes in the mix of earnings amongst jurisdictions with differing statutory tax rates (including as a result of business acquisitions and dispositions), changes in the valuation of deferred tax assets and liabilities, the results of audits and examinations of previously file d tax returns, tax planning initiatives, tax characteristics of income, as well as the timing and deductibility of expenses for tax purposes. The Company's effective tax rate dif fers from the U.S. federal statutory rate of 35% primaril y as a result of lowe r statutory tax rates on foreign earnings at the Company’s operations outside of the United States. The distribution of lower-taxed foreign earnings to the U.S. would generally increase the Company's effective tax rate. With limited exception, the Company and its subsidiaries are no longer subject to U.S. federal, state and local or non-U.S. income tax examinations by taxing authorities for tax returns filed with respect to periods prior to fiscal year 2009. The Company makes no provision for deferred U.S. income taxes on undistributed foreign earnings because as of June 30, 2015 , it remained management’s intention to continue to indefinitely reinvest such earnings in foreign operations . In making this determination, the Company also e valuates its expected cash requirements in the United States. These earnings relate to ongoing operations and, as of June 30, 2015 , the approximate amount of undistributed foreign earnings amounted to $ 661 million. Because of the availability of U.S. foreign tax credits as well as other factors, it is not practicable to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely.

Income per Share

Income per Share	9 Months Ended
	Jun. 30, 2015
Income per Share [Abstract]
Income per Share	9 INCOME PER SHARE The computation of basic and diluted income per share is as follows: Income per Share Three months ended Nine months ended June 30, June 30, (In millions, except share and per share amounts) 2015 2014 2015 2014 Net income attributable to Sirona Dental Systems, Inc. common shareholders $ 58.8 $ 51.5 $ 140.8 $ 133.0 Weighted average shares outstanding - basic 55,706,017 55,362,620 55,568,488 55,251,782 Dilutive effect of stock-based compensation (1) 690,803 875,456 790,455 949,576 Weighted average shares outstanding - diluted 56,396,820 56,238,076 56,358,943 56,201,358 Net income per share Basic $ 1.06 $ 0.93 $ 2.53 $ 2.41 Diluted $ 1.04 $ 0.92 $ 2.50 $ 2.37 (1) There were no stock options excluded from the computation of diluted earnings per share for the periods under report.

Segment Reporting

Segment Reporting	9 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segment reporting	10 SEGMENT REPORTING SEGME NT RESULTS The following tables reflect the results of the Company’s reportable segments under the Company’s management reporting system. The segment performance measure used to monitor segment performance is gross profit (‘‘Segment Performance Measure ’’) excluding the impact of the acquisition of control of the Sirona business by Sirona Holdings Luxco S.C.A. (“ Luxco ”) – the former controlling shareholder , a Luxembourg-based holding entity owned by funds managed by Madison Dearborn Partners (“MDP”); Beecken Petty O’Keefe and management of Sirona through a leveraged buyout transaction on June 30, 2005 (the “MDP Transaction”) ; and the Exchange . This measure is considered by management to better reflect the performance of each segment as it eliminates the need to allocate centrally incurred costs and significant purchase accounting impacts that the Company does not believe are representative of the performance of the segments. Furthermore, the Company monitors performance geogra phically by region. As the Company manages its business on both a product and a geographical basis, U.S. GAAP requires segmental disclosure based on product information. Segment Performance Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Revenue External Dental CAD/CAM Systems $ 121.8 $ 109.3 $ 321.8 $ 324.0 Imaging Systems 103.7 109.1 292.4 302.9 Treatment Centers 53.8 51.2 157.0 162.6 Instruments 26.8 30.1 85.2 91.6 Total $ 306.1 $ 299.7 $ 856.4 $ 881.1 Segment performance measure (gross profit) Dental CAD/CAM Systems $ 85.4 $ 75.3 $ 225.0 $ 221.6 Imaging Systems 61.2 65.8 170.4 177.0 Treatment Centers 22.4 19.8 65.2 64.5 Instruments 10.0 12.9 33.7 37.6 Total Segments $ 179.0 $ 173.8 $ 494.3 $ 500.7 RECONCILIATION OF THE RESULTS OF THE SEGMENT PERFORMANCE MEASURE TO THE CONSOLIDATED STATEMENTS OF INCOME The following table provide s a reconciliation of the total results of operations of the Company’s business segments under management reporting to the consolidated financial statements. The differences shown between management reporting and U.S. GAAP for the three and nine months ended June 30, 2015 and 2014 are due to the impac t of purchase accounting and certain other corporate items . These effects are not included in the segment performance measure as the Company does not believe these to be representative of the performance of each segment. Reconciliation of Segment Performance Measure to Consolidated Statement of Income Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Consolidated revenue $ 306.1 $ 299.7 $ 856.4 $ 881.1 Segment performance measure (gross profit) Total segments 179.0 173.8 494.3 500.7 Differences management reporting vs. U.S. GAAP (including step-up depreciation and amortization and certain other corporate items) (4.4) (6.2) (13.0) (18.9) Consolidated gross profit 174.6 167.6 481.3 481.8 Selling, general and administrative expense (84.0) (88.1) (253.9) (263.3) Research and development expense (12.9) (16.6) (41.9) (48.1) Net other operating income (loss) 2.7 4.4 7.7 9.4 Gain (loss) on foreign currency transactions (5.1) 2.2 (6.4) 1.6 Gain (loss) on derivative instruments 4.0 (0.5) 1.7 (1.4) Interest income (expense) (1.0) (0.7) (2.7) (2.4) Other income (expense) (1.1) (0.6) (0.6) (1.5) Income before taxes $ 77.2 $ 67.7 $ 185.2 $ 176.1 CONCENTRATION OF REVENUE A substantial portion of our revenue comes from two distributors accounting for more than 10% of revenues. Patterson Companies, Inc. (“Patterson”) and Henry Schein, Inc. (“Henry Schein”) accounted for revenues and accounts receivable for the three and nine months ended June 30, 2015 compared to the three and nine months ended June 30, 2014 as shown in the table below. These revenu es were earned across all segments, with a significant portion of revenues with Patterson being earned in the CAD/CAM and Imaging segments. No other customer accounted for more than 10% of revenues. Concentration of Revenue Three months ended Nine months ended June 30, June 30, (In millions, except for percent amounts) 2015 2014 2015 2014 Top Customers Revenues Patterson Dental Company, Inc. 34% 36% 35% 33% Henry Schein, Inc. 16% 13% 15% 13% Total of customers > 10% revenues 50% 49% 50% 46% Accounts Receivable Patterson Dental Company, Inc. $ 86.5 $ 75.1 Henry Schein, Inc. 18.6 14.2 Total Accounts Receivable of customers > 10% revenues $ 105.1 $ 89.3

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income/(Loss)	9 Months Ended
	Jun. 30, 2015
Accumulated Other Comprehensive Income/(Loss) [Abstract]
Accumulated Other Comprehensive Income	11 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) The components and development of accumulated other comprehensive income (loss) for the periods under report are as follows: Accumulated Other Comprehensive Income (Loss) Three months ended June 30, 2015 (In millions) Cumulative translation adjustments Unrecognized elements of pension cost Net gain (loss) from hedging instruments Total Balance at beginning of period $ (230.8) $ 10.9 $ (0.3) $ (220.2) Current increase (decrease) 35.4 0.4 0.2 36.0 Income tax (expense) benefit - (0.1) (0.1) (0.2) Balance at end of period (195.4) 11.2 (0.2) (184.4) Other comprehensive income (loss) attributable to noncontrolling interests, net of tax 0.1 - - 0.1 Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders $ (195.5) $ 11.2 $ (0.2) $ (184.5) Accumulated Other Comprehensive Income (Loss) Three months ended June 30, 2014 (In millions) Cumulative translation adjustments Unrecognized elements of pension cost Net gain (loss) from hedging instruments Total Balance at beginning of period $ 20.6 $ 6.5 $ (0.5) $ 26.6 Current increase (decrease) (9.9) (0.2) - (10.1) Income tax (expense) benefit - - 0.1 0.1 Balance at end of period 10.7 6.3 (0.4) 16.6 Other comprehensive income (loss) attributable to noncontrolling interests, net of tax (0.1) - - (0.1) Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders $ 10.8 $ 6.3 $ (0.4) $ 16.7 Accumulated Other Comprehensive Income (Loss) Nine months ended June 30, 2015 (In millions) Cumulative translation adjustments Unrecognized elements of pension cost Net gain (loss) from hedging instruments Total Balance at beginning of period $ (85.6) $ 13.2 $ (0.4) $ (72.8) Current increase (decrease) (110.1) (2.8) 0.3 (112.6) Income tax (expense) benefit - 0.8 (0.1) 0.7 Balance at end of period (195.7) 11.2 (0.2) (184.7) Other comprehensive income (loss) attributable to noncontrolling interests, net of tax (0.2) - - (0.2) Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders $ (195.5) $ 11.2 $ (0.2) $ (184.5) Accumulated Other Comprehensive Income (Loss) Nine months ended June 30, 2014 (In millions) Cumulative translation adjustments Unrecognized elements of pension cost Net gain (loss) from hedging instruments Total Balance at beginning of period $ 2.9 $ 6.4 $ (0.7) $ 8.6 Current increase (decrease) 7.9 (0.1) 0.2 8.0 Income tax (expense) benefit - - 0.1 0.1 Balance at end of period 10.8 6.3 (0.4) 16.7 Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders $ 10.8 $ 6.3 $ (0.4) $ 16.7

Inventories, net

Inventories, net	9 Months Ended
	Jun. 30, 2015
Inventories, net [Abstract]
Inventories, net	12 INVENTORIES, NET The components of net inventories for the periods under report are as follows: Inventories June 30, September 30, (In millions) 2015 2014 Finished goods $ 98.7 $ 86.8 Work in progress 14.1 14.3 Raw materials 39.0 39.7 Inventories, gross 151.8 140.8 Inventory reserve (19.4) (17.4) Inventories, net $ 132.4 $ 123.4

Product Warranty

Product Warranty	9 Months Ended
	Jun. 30, 2015
Product warranty [Abstract]
Product warranty	13 PRODUCT WARRANTY The following table provides the components of and changes in the product warranty accrual for the periods under re port : Product Warranty Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Balance at beginning of the period $ 6.7 $ 10.0 $ 7.6 $ 9.7 Accruals for warranties issued 8.1 5.2 17.7 15.7 Warranty settlements made (7.6) (6.0) (17.2) (16.4) Translation adjustment 0.2 (0.1) (0.7) 0.1 Balance at end of the period $ 7.4 $ 9.1 $ 7.4 $ 9.1

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Jun. 30, 2015
Fair Value Measurements [Abstract]
Fair Value Measurements	14 FAIR VALUE MEASUREMENTS T he Compan y applies the provisions of ASC 820, Fair Value Measurements and Disclosures , for assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilit ies that are required to be recorded or disclosed at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions, and the credit risk of the Company and counterparties to the arrangement. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure f air value into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is available and significant to the fair value measurement. ASC 820 establishes and prioritizes the following three levels of inputs that may be used to measure fair value: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Inputs that are generall y unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. FAIR VALUE OF FINANCIAL INSTRUMENTS Financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, foreign currency forward contracts, interest rate swaps, and certain liabilities related to business acquisitions primarily resulting from earn-out features. The carrying amounts of cash, cash equivalents, accounts receivable and accounts payable approximate their respective fair values because of the short maturity and nature of these items. The fair value of the foreign currency forward contracts and interest rate swaps is determined by the estimated cash flows of those contr acts and swaps. The fair values of the acquisition-related liabilities are based on discounted valuations of commercial assumptions made by Company management of stipulations governed in the underlying purchase agreements. ASSETS/LIABILITIES MEASURED AT F AIR VALUE ON A RECURRING BASIS The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis for the periods under report: Assets and Liabilities Measured at Fair Value - Recurring Basis June 30, 2015 Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total (In millions) Foreign Exchange Assets Cash Equivalents (money market funds) $ 218.7 $ - $ - $ 218.7 Derivative Assets - 0.7 - 0.7 Liabilities Derivative Liabilities - (0.2) - (0.2) Business Combination-related liabilities - - (13.0) (13.0) Total $ 218.7 $ 0.5 $ (13.0) $ 206.2 Assets and Liabilities Measured at Fair Value - Recurring Basis September 30, 2014 Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total (In millions) Foreign Exchange Assets Cash Equivalents (money market funds) $ 211.2 $ - $ - $ 211.2 Liabilities Derivative Liabilities - (1.5) - (1.5) Business Combination-related liabilities - - (14.2) (14.2) Total $ 211.2 $ (1.5) $ (14.2) $ 195.5 The change in the fair value of the business acquisition-related liabilities was a $1.2 million decrease for the period under report, of which a total for all acquisitions of $ 0.3 million (expense) and $0.4 million (income) was recorded in other income ( expense ) in the income statement for the three and nine months ended June 30, 2015 , respectively. In the Company’s June 30, 2015 and September 30, 2014 Consolidated Balance Sheet, derivati ve assets and derivative liabilities are classified as prepaid expenses and other current assets and accrued liabilities and deferred income, respectively. The Company did not elect the fair value option for any other eligible financial instruments .

General (Policies)

General (Policies)	9 Months Ended
	Jun. 30, 2015
General [Abstract]
The Company and its Operations	THE COMPANY AND ITS O PERATIONS Sirona Dental Systems, Inc. (“Sirona,” the “Company,” “we,” “us,” and “our” refer to Sirona Dental Systems, Inc. and its consolidated subsidiaries) is the leading global manufacturer o f high-quality, technologically- advanced dental equipment, and is focuse d on developing, manufacturing , and marketing innovative systems and solutions for dentists around the world. We offer a broad range of products across all major segments of the dental technology mark et including CEREC and our other CAD/CAM systems, digita l intra oral and 2D and 3D panoramic imaging systems, treatment centers , and instruments. The Company acquired Schick Technologies, Inc. (“Schick”) in 2006, in a transaction accounted for as a reverse acquisition (the “Exchange”), further expanding our glo bal presence and product offerings and strengthening our research and development capabilities. Sirona has served equipment dealers and dentists worldwide for more than 130 years. The Company’s headqu arters is located in Long Island City, New York with its primary facility located in Bensheim , Germany, as well as other support, manufacturing, assembling, and sales and service facilities lo cated around the globe.
Basis of Presentation	BASIS OF PRESENTATION The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with acco unting principles generally accepted in the United States (“U.S. GAAP”). All amounts are reported in millions of U.S. Dollars ($), except per share amounts or as otherwise disclosed.
Fiscal year	Fiscal Year The Company’s fi scal year is October 1 to September 30.
Principles of consolidation	Principles of Consolidation The consolidated financial statements include, after eliminating inter-company transactions and balances, the accounts of Sirona Dental Systems, Inc. and its subsidiaries.
Use of Estimates	Use of Estimat es Preparation of the interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions related to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as at th e reporting date and the reported amounts of revenues and expenses for the interim period. Actual results could differ from those estimates. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information not misleading. The year-end consolidated financial data was derived from the audited c onsolidated financial statements, but does not include all disclosures required by U.S. GAAP. These condensed c onsolidated financial statements should be read in conjunction with the Consolidated Financial Statements and the Notes thereto included in the C ompany’s Annual Report on Form 10-K for the fisc al year ended September 30, 2014 . In the opinion of management, all adjustments considered necessary to present fairly the Company’s f inancial position as of June 30, 2015 , and the results of operations and cash flows for the nine months ended June 30, 2015 and 2014 , respectively, as applicable to interim periods have been made. The results of operations for the nine months ended June 30, 2015 are not necessarily indicative of the operating results for the full fiscal year or future periods.
Foreign Currency	Foreign Currency The functional currency for foreign operations has been determined in all cases to be the local currency. Assets and liabilities of foreign subsidiaries are translated into U.S. Dollars using period-end exchange rates, while revenues and expenses are translated into U.S. Dollars using weighted average exchange rates for the period. Resulting adjustme nts are recorded in shareholders’ equity as a component of accumulated other comprehensive income . Gains or losses resulting from transactions in other than the functional currency are reflected in the consolidated statements of income in Gain (loss) on fo reign currency transactions , except for intra-group transactions of a long-term nature, which are recorded in shareholders’ equity as a component of accumulated other comprehensive income .
Derivative Instruments and Hedging Strategies	DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES RISK S AND EXPOSURE Our operations are exposed to market risks from changes in foreign currency exchange rates and interest rates. In the normal course of business, these risks are managed through a variety of strategies, including the use of derivatives. Interest Rate Risk The Company is exposed to interest rate risk associated with fluctuations in the interest rates on its variable interest rate debt. In order to manage this risk, the Company enters into interest rate swap agreements, when appropriate, based upon market conditions. Foreign Currency Exposure Although the U.S. Dollar is Sirona’s reporting currency, it conducts its business in many currencies, and its local functional currency varies depend ing on the country of operation, which exposes the Company to market risk associated with foreign currency exchange rate movements. The Company hedge s certain foreign currency transaction exposure through foreign exchange forward contracts. Interest Rate The Company uses interest rate swaps to convert a portion of its debt's variable interest rate to a fixed interest rate .
Fair Value of Financial Instruments	FAIR VALUE OF FINANCIAL INSTRUMENTS Financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, foreign currency forward contracts, interest rate swaps, and certain liabilities related to business acquisitions primarily resulting from earn-out features. The carrying amounts of cash, cash equivalents, accounts receivable and accounts payable approximate their respective fair values because of the short maturity and nature of these items. The fair value of the foreign currency forward contracts and interest rate swaps is determined by the estimated cash flows of those contr acts and swaps. The fair values of the acquisition-related liabilities are based on discounted valuations of commercial assumptions made by Company management of stipulations governed in the underlying purchase agreements.

Employee Share-Based Compensa22

Employee Share-Based Compensation (Tables)	9 Months Ended
	Jun. 30, 2015
Employee Share-Based Compensation [Abstract]
Schedule of Black-Scholes assumptions (option pricing)	Black-Scholes Assumptions Nine months ended Year ended June 30, September 30, 2015 2014 Expected Volatility 26.77% 33.27% Risk-free rate 1.58% 1.35% Expected term 5 years 5 years Expected dividends - -
Schedule of compensation expense and other information	Compensation Expense Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Compensation expense (1) $ 3.5 $ 2.8 $ 10.1 $ 9.2 (1) For the first nine months of fiscal years 2015 and 2014, this included a compensation charge of $0.5 million and $0.9 million, respectively, for share-based awards in connection with the CFO Transition.
Schedule of restricted and performance-based stock unit activity	RSU and PSU Activity Nine months ended June 30, 2015 Restricted stock units Performance-based stock units Number of shares Weighted average market price at grant Number of shares Weighted average market price at grant Outstanding at beginning of period 491,781 $ 55.81 42,566 $ 66.63 Granted 139,387 87.63 37,004 86.00 Vested (182,170) 47.05 - - Forfeited (6,325) 62.48 - - Outstanding at end of period 442,673 $ 69.33 79,570 $ 75.64
Schedule of stock option activity	Stock Option Activity Nine months ended June 30, 2015 Number of options Weighted average exercise price Outstanding at beginning of period 1,560,592 $ 29.13 Granted 160,262 86.00 Exercised (711,489) 16.49 Forfeited (3,163) 51.59 Outstanding at end of period 1,006,202 $ 47.06 thereof vested and exercisable 591,925

Net Other Operating Income (L23

Net Other Operating Income (Loss) (Table)	9 Months Ended
	Jun. 30, 2015
Net Other Operating Income (Loss)[Abstract]
Schedule of net other operating income (loss)	Net Other Operating Income (Loss) Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment $ 2.5 $ 2.5 $ 7.5 $ 7.5 Gain from patent infringement settlement (1) 0.1 - 0.1 - Other miscellaneous gain (loss) (2) 0.1 1.9 0.1 1.9 Net other operating income (loss) $ 2.7 $ 4.4 $ 7.7 $ 9.4 (1) The gain from patent infringement settlement for the three months ended June 30, 2015, represents amounts received for past lost profits in an out-of-court settlement of a patent defense suit in the normal course of business. (2) The other miscellaneous gain for the three months ended June 30, 2014, represents a gain on disposal of certain business assets.
Schedule of deferred income	Deferred Income (Patterson Exclusivity Payment) Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Foreign currency transaction gain (loss) resulting from the remeasurement of the deferred income related to the Patterson exclusivity payment $ 0.8 $ (0.3) $ (3.4) $ 0.5

Derivative Instruments and He24

Derivative Instruments and Hedging Strategies (Tables)	9 Months Ended
	Jun. 30, 2015
Derivative Instruments And Hedging Strategies [Abstract]
Schedule of derivative instruments, location and amount of gains and losses	Derivatives Designated as Cash Flow Hedging Instruments Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Income For the three months ended For the nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Interest rate swap contracts $ 0.2 $ - $ 0.3 $ 0.2 Total $ 0.2 $ - $ 0.3 $ 0.2 Derivatives Not Designated as Hedging Instruments Amount of Gain (Loss) Recognized in Income on Derivative Instruments Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Affected Line Item in the Statement of Income Foreign exchange contracts $ 4.0 $ (0.5) $ 1.7 $ (1.4) Gain (loss) on derivative instruments, net

Income per Share (Tables)

Income per Share (Tables)	9 Months Ended
	Jun. 30, 2015
Income per Share [Abstract]
Schedule of income per share	Income per Share Three months ended Nine months ended June 30, June 30, (In millions, except share and per share amounts) 2015 2014 2015 2014 Net income attributable to Sirona Dental Systems, Inc. common shareholders $ 58.8 $ 51.5 $ 140.8 $ 133.0 Weighted average shares outstanding - basic 55,706,017 55,362,620 55,568,488 55,251,782 Dilutive effect of stock-based compensation (1) 690,803 875,456 790,455 949,576 Weighted average shares outstanding - diluted 56,396,820 56,238,076 56,358,943 56,201,358 Net income per share Basic $ 1.06 $ 0.93 $ 2.53 $ 2.41 Diluted $ 1.04 $ 0.92 $ 2.50 $ 2.37 (1) There were no stock options excluded from the computation of diluted earnings per share for the periods under report.

Segment reporting (Tables)

Segment reporting (Tables)	9 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Schedule of segment reporting information by segment	Segment Performance Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Revenue External Dental CAD/CAM Systems $ 121.8 $ 109.3 $ 321.8 $ 324.0 Imaging Systems 103.7 109.1 292.4 302.9 Treatment Centers 53.8 51.2 157.0 162.6 Instruments 26.8 30.1 85.2 91.6 Total $ 306.1 $ 299.7 $ 856.4 $ 881.1 Segment performance measure (gross profit) Dental CAD/CAM Systems $ 85.4 $ 75.3 $ 225.0 $ 221.6 Imaging Systems 61.2 65.8 170.4 177.0 Treatment Centers 22.4 19.8 65.2 64.5 Instruments 10.0 12.9 33.7 37.6 Total Segments $ 179.0 $ 173.8 $ 494.3 $ 500.7
Schedule of reconciliation of operating profit (loss) from segments to consolidated	Reconciliation of Segment Performance Measure to Consolidated Statement of Income Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Consolidated revenue $ 306.1 $ 299.7 $ 856.4 $ 881.1 Segment performance measure (gross profit) Total segments 179.0 173.8 494.3 500.7 Differences management reporting vs. U.S. GAAP (including step-up depreciation and amortization and certain other corporate items) (4.4) (6.2) (13.0) (18.9) Consolidated gross profit 174.6 167.6 481.3 481.8 Selling, general and administrative expense (84.0) (88.1) (253.9) (263.3) Research and development expense (12.9) (16.6) (41.9) (48.1) Net other operating income (loss) 2.7 4.4 7.7 9.4 Gain (loss) on foreign currency transactions (5.1) 2.2 (6.4) 1.6 Gain (loss) on derivative instruments 4.0 (0.5) 1.7 (1.4) Interest income (expense) (1.0) (0.7) (2.7) (2.4) Other income (expense) (1.1) (0.6) (0.6) (1.5) Income before taxes $ 77.2 $ 67.7 $ 185.2 $ 176.1
Schedule of concentration of revenue	Concentration of Revenue Three months ended Nine months ended June 30, June 30, (In millions, except for percent amounts) 2015 2014 2015 2014 Top Customers Revenues Patterson Dental Company, Inc. 34% 36% 35% 33% Henry Schein, Inc. 16% 13% 15% 13% Total of customers > 10% revenues 50% 49% 50% 46% Accounts Receivable Patterson Dental Company, Inc. $ 86.5 $ 75.1 Henry Schein, Inc. 18.6 14.2 Total Accounts Receivable of customers > 10% revenues $ 105.1 $ 89.3

Accumulated Other Comprehensi27

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Jun. 30, 2015
Accumulated Other Comprehensive Income/(Loss) [Abstract]
Schedule of Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Three months ended June 30, 2015 (In millions) Cumulative translation adjustments Unrecognized elements of pension cost Net gain (loss) from hedging instruments Total Balance at beginning of period $ (230.8) $ 10.9 $ (0.3) $ (220.2) Current increase (decrease) 35.4 0.4 0.2 36.0 Income tax (expense) benefit - (0.1) (0.1) (0.2) Balance at end of period (195.4) 11.2 (0.2) (184.4) Other comprehensive income (loss) attributable to noncontrolling interests, net of tax 0.1 - - 0.1 Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders $ (195.5) $ 11.2 $ (0.2) $ (184.5) Accumulated Other Comprehensive Income (Loss) Three months ended June 30, 2014 (In millions) Cumulative translation adjustments Unrecognized elements of pension cost Net gain (loss) from hedging instruments Total Balance at beginning of period $ 20.6 $ 6.5 $ (0.5) $ 26.6 Current increase (decrease) (9.9) (0.2) - (10.1) Income tax (expense) benefit - - 0.1 0.1 Balance at end of period 10.7 6.3 (0.4) 16.6 Other comprehensive income (loss) attributable to noncontrolling interests, net of tax (0.1) - - (0.1) Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders $ 10.8 $ 6.3 $ (0.4) $ 16.7 Accumulated Other Comprehensive Income (Loss) Nine months ended June 30, 2015 (In millions) Cumulative translation adjustments Unrecognized elements of pension cost Net gain (loss) from hedging instruments Total Balance at beginning of period $ (85.6) $ 13.2 $ (0.4) $ (72.8) Current increase (decrease) (110.1) (2.8) 0.3 (112.6) Income tax (expense) benefit - 0.8 (0.1) 0.7 Balance at end of period (195.7) 11.2 (0.2) (184.7) Other comprehensive income (loss) attributable to noncontrolling interests, net of tax (0.2) - - (0.2) Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders $ (195.5) $ 11.2 $ (0.2) $ (184.5) Accumulated Other Comprehensive Income (Loss) Nine months ended June 30, 2014 (In millions) Cumulative translation adjustments Unrecognized elements of pension cost Net gain (loss) from hedging instruments Total Balance at beginning of period $ 2.9 $ 6.4 $ (0.7) $ 8.6 Current increase (decrease) 7.9 (0.1) 0.2 8.0 Income tax (expense) benefit - - 0.1 0.1 Balance at end of period 10.8 6.3 (0.4) 16.7 Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders $ 10.8 $ 6.3 $ (0.4) $ 16.7

Inventories, net (Tables)

Inventories, net (Tables)	9 Months Ended
	Jun. 30, 2015
Inventories, net [Abstract]
Schedule of inventories, net	Inventories June 30, September 30, (In millions) 2015 2014 Finished goods $ 98.7 $ 86.8 Work in progress 14.1 14.3 Raw materials 39.0 39.7 Inventories, gross 151.8 140.8 Inventory reserve (19.4) (17.4) Inventories, net $ 132.4 $ 123.4

Product warranty (Tables)

Product warranty (Tables)	9 Months Ended
	Jun. 30, 2015
Product warranty [Abstract]
Schedule of product warranty	Product Warranty Three months ended Nine months ended June 30, June 30, (In millions) 2015 2014 2015 2014 Balance at beginning of the period $ 6.7 $ 10.0 $ 7.6 $ 9.7 Accruals for warranties issued 8.1 5.2 17.7 15.7 Warranty settlements made (7.6) (6.0) (17.2) (16.4) Translation adjustment 0.2 (0.1) (0.7) 0.1 Balance at end of the period $ 7.4 $ 9.1 $ 7.4 $ 9.1

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Jun. 30, 2015
Fair Value Measurements [Abstract]
Schedule of fair value by Balance Sheet grouping	Assets and Liabilities Measured at Fair Value - Recurring Basis June 30, 2015 Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total (In millions) Foreign Exchange Assets Cash Equivalents (money market funds) $ 218.7 $ - $ - $ 218.7 Derivative Assets - 0.7 - 0.7 Liabilities Derivative Liabilities - (0.2) - (0.2) Business Combination-related liabilities - - (13.0) (13.0) Total $ 218.7 $ 0.5 $ (13.0) $ 206.2 Assets and Liabilities Measured at Fair Value - Recurring Basis September 30, 2014 Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total (In millions) Foreign Exchange Assets Cash Equivalents (money market funds) $ 211.2 $ - $ - $ 211.2 Liabilities Derivative Liabilities - (1.5) - (1.5) Business Combination-related liabilities - - (14.2) (14.2) Total $ 211.2 $ (1.5) $ (14.2) $ 195.5

Business Acquisitions (Details)

Business Acquisitions (Details) - USD ($) $ in Millions	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2014
Business Combination, Additional Disclosures [Abstract]
Business acquisitions in the current period	$ (1.2)
Goodwill	$ 587.5	$ 629.3
Dental Company
Business Acquisition, Entity Acquired And Reason For Acquisition [Abstract]
Business Acquisition, Percentage Of Voting Interests Acquired	100.00%
Business Combination, Additional Disclosures [Abstract]
Consideration transferred	$ 18.6
Goodwill	$ 15.8

Employee Share-Based Compensa32

Employee Share-Based Compensation (Details) - $ / shares	9 Months Ended	12 Months Ended
	Jun. 30, 2015	Sep. 30, 2014
Equity incentive plan
Share-based compensation, options granted in period	160,262
Share-based compensation, grants in period weighted average exercised price	$ 86
Share-based compensation, weighted average grant date fair value	$ 22.9
Stock Options
Equity incentive plan
Share-based compensation, options expiration date	10 years
Stock Options | Minimum
Equity incentive plan
Share-based compensation, award vesting period	4 years
Stock Options | Maximum
Equity incentive plan
Share-based compensation, award vesting period	5 years
2006 Plan
Equity incentive plan
Share-based compensation, total number of stock options authorized	4,550,000
Share-based compensation, number of shares available for future grant	0
2006 Plan | RSU
Equity incentive plan
Granted, weighted average market price at grant	$ 87.29
Granted, number of shares	139,387
2006 Plan | RSU | Minimum
Equity incentive plan
Share-based compensation, award vesting period	4 years
2006 Plan | RSU | Maximum
Equity incentive plan
Share-based compensation, award vesting period	5 years
2006 Plan | PSU
Equity incentive plan
Share-based compensation, award vesting period	3 years
Granted, weighted average market price at grant	$ 87.29
Granted, number of shares	37,004
2006 Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected Volatility	26.77%	33.27%
Risk-free rate	1.58%	1.35%
Expected term	5 years	5 years
Expected dividends	0.00%	0.00%
2015 Plan
Equity incentive plan
Share-based compensation, total number of stock options authorized	6,825,000
Share-based compensation, number of shares available for future grant	6,804,157

Employee Share-Based Compensa33

Employee Share-Based Compensation (Details 1) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Compensation Expense	$ 3.5	$ 2.8	$ 10.1	$ 9.2
Compensation charge in connection with CFO and CEO and Chairman Transition			$ 0.5	$ 0.9

Employee Share-Based Compensa34

Employee Share-Based Compensation (Details 2) - 9 months ended Jun. 30, 2015 - $ / shares	Total
RSU
Restricted and Performance-Based Stock Unit Activity
Outstanding at beginning of period, number of shares	491,781
Granted, number of shares	139,387
Vested, number of shares	(182,170)
Forfeited, number of shares	(6,325)
Outstanding at end of period, number of shares	442,673
Outstanding at beginning of period, weighted average market price at grant	$ 55.81
Granted, weighted average market price at grant	87.63
Vested, weighted average market price at grant	47.05
Forfeited, weighted average market price at grant	62.48
Outstanding at end of period, weighted average market price at grant	$ 69.33
PSU
Restricted and Performance-Based Stock Unit Activity
Outstanding at beginning of period, number of shares	42,566
Granted, number of shares	37,004
Vested, number of shares	0
Forfeited, number of shares	0
Outstanding at end of period, number of shares	79,570
Outstanding at beginning of period, weighted average market price at grant	$ 66.63
Granted, weighted average market price at grant	86
Vested, weighted average market price at grant	0
Forfeited, weighted average market price at grant	0
Outstanding at end of period, weighted average market price at grant	$ 75.64

Employee Share-Based Compensa35

Employee Share-Based Compensation (Details 3) - Jun. 30, 2015 - $ / shares	Total
Stock option activity
Outstanding at beginning of period, number of options	1,560,592
Granted, number of options	160,262
Exercised, number of options	(711,489)
Forfeited, number of options	(3,163)
Outstanding at end of period, number of options	1,006,202
thereof vested and exercisable	591,925
Stock option activity, weighted average exercise price
Outstanding at beginning of period, weighted average exercise price	$ 29.13
Granted, weighted average exercise price	86
Exercised, weighted average exercise price	16.49
Forfeited, weighted average exercise price	51.59
Outstanding at end of period, weighted average exercise price	$ 47.06

Net Other Operating Income (L36

Net Other Operating Income (Loss)(Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Net Other Operating Income (Loss)[Abstract]
Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment	$ 2.5	$ 2.5	$ 7.5	$ 7.5
Gain from patent infringement settlement	0.1	0	0.1	0
Other miscellaneous gain (loss)	0.1	1.9	0.1	1.9
Net other operating income (loss)	$ 2.7	$ 4.4	$ 7.7	$ 9.4

Net Other Operating Income (L37

Net Other Operating Income (Loss)(Details 1) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Deferred Revenue Arrangement [Line Items]
Gain (loss) on foreign currency transactions, net	$ (5.1)	$ 2.2	$ (6.4)	$ 1.6
Exclusivity Payment, Patterson
Deferred Revenue Arrangement [Line Items]
Gain (loss) on foreign currency transactions, net	$ 0.8	$ (0.3)	$ (3.4)	$ 0.5

Derivative Instruments and He38

Derivative Instruments and Hedging Strategies (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Designated as Hedging Instrument
Impact of gains and losses from the fair value changes of the derivative instruments
Gain (Loss) Recognized in Accumulated Other Comprehensive Income	$ 0.2	$ 0	$ 0.3	$ 0.2
Interest rate swap contracts
Interest Rate Risk
Percentage of Debt Hedged by Interest Rate Derivatives	100.00%		100.00%
Derivative, Lower Fixed Interest Rate Range	1.27%		1.27%
Derivative, Higher Fixed Interest Rate Range	1.285%		1.285%
Interest rate swap contracts | Designated as Hedging Instrument
Impact of gains and losses from the fair value changes of the derivative instruments
Gain (Loss) Recognized in Accumulated Other Comprehensive Income	$ 0.2	0	$ 0.3	0.2
Foreign exchange contracts
Foreign Currency Exposure
Notional Amount	36.1		36.1
Foreign exchange contracts | Gain (loss) on derivative instruments, net | Not Designated as Hedging Instrument
Impact of gains and losses from the fair value changes of the derivative instruments
Gain (Loss) Recognized in Income	$ 4	$ (0.5)	$ 1.7	$ (1.4)

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014
Income Taxes [Abstract]
Estimated effective tax rate			23.00%	23.50%
Income tax provision	$ 17.8	$ 15.9	$ 42.6	$ 41.4
Actual effective tax rate					23.00%
United States federal statutory rate			35.00%
Undistributed foreign earnings	$ 661		$ 661

Income per Share (Details)

Income per Share (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income per Share [Abstract]
Net income attributable to Sirona Dental Systems, Inc. common shareholders	$ 58.8	$ 51.5	$ 140.8	$ 133
Weighted average shares outstanding - basic	55,706,017	55,362,620	55,568,488	55,251,782
Dilutive effect of stock-based compensation	690,803	875,456	790,455	949,576
Weighted average shares - diluted	56,396,820	56,238,076	56,358,943	56,201,358
Net income per share
Basic	$ 1.06	$ 0.93	$ 2.53	$ 2.41
Diluted	$ 1.04	$ 0.92	$ 2.5	$ 2.37

Segment reporting (Details)

Segment reporting (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue
Total	$ 306.1	$ 299.7	$ 856.4	$ 881.1
Dental CAD/CAM Systems
Revenue
Total	121.8	109.3	321.8	324
Segment Performance Measure
Total	85.4	75.3	225	221.6
Imaging Systems
Revenue
Total	103.7	109.1	292.4	302.9
Segment Performance Measure
Total	61.2	65.8	170.4	177
Treatment Centers
Revenue
Total	53.8	51.2	157	162.6
Segment Performance Measure
Total	22.4	19.8	65.2	64.5
Instruments
Revenue
Total	26.8	30.1	85.2	91.6
Segment Performance Measure
Total	10	12.9	33.7	37.6
Total segments
Segment Performance Measure
Total	$ 179	$ 173.8	$ 494.3	$ 500.7

Segment reporting (Details 1)

Segment reporting (Details 1) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue
Consolidated revenue	$ 306.1	$ 299.7	$ 856.4	$ 881.1
Segement performance measure
Consolidated gross profit	174.6	167.6	481.3	481.8
Selling, general and administrative expense	(84)	(88.1)	(253.9)	(263.3)
Research and development expense	(12.9)	(16.6)	(41.9)	(48.1)
Net other operating income (loss)	2.7	4.4	7.7	9.4
Gain (loss) on foreign currency transactions	(5.1)	2.2	(6.4)	1.6
Gain (loss) on derivative instruments	4	(0.5)	1.7	(1.4)
Interest income (expense)	(1)	(0.7)	(2.7)	(2.4)
Other income (expense)	(1.1)	(0.6)	(0.6)	(1.5)
INCOME BEFORE TAXES	77.2	67.7	185.2	176.1
Total segments
Segement performance measure
Consolidated gross profit	179	173.8	494.3	500.7
Differences management reporting vs. US GAAP (including step-up depreciation and certain other corporate items)
Segement performance measure
Consolidated gross profit	$ (4.4)	$ (6.2)	$ (13)	$ (18.9)

Segment reporting (Details 2)

Segment reporting (Details 2) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014
Concentration Risk [Line Items]
Accounts Receivable Net Current	$ 184		$ 184		$ 115.6
Sales Revenue, Goods, Net [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	50.00%	49.00%	50.00%	46.00%
Sales Revenue, Goods, Net [Member] | Patterson Dental Company, Inc.
Concentration Risk [Line Items]
Concentration Risk, Percentage	34.00%	36.00%	35.00%	33.00%
Sales Revenue, Goods, Net [Member] | Henry Schein, Inc.
Concentration Risk [Line Items]
Concentration Risk, Percentage	16.00%	13.00%	15.00%	13.00%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Accounts Receivable Net Current	$ 105.1	$ 89.3	$ 105.1	$ 89.3
Accounts Receivable [Member] | Patterson Dental Company, Inc.
Concentration Risk [Line Items]
Accounts Receivable Net Current	86.5	75.1	86.5	75.1
Accounts Receivable [Member] | Henry Schein, Inc.
Concentration Risk [Line Items]
Accounts Receivable Net Current	$ 18.6	$ 14.2	$ 18.6	$ 14.2

Accumulated Other Comprehensi44

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Balance at beginning of period	$ (220.2)	$ 26.6	$ (72.8)	$ 8.6
Current increase (decrease)	36	(10.1)	(112.6)	8
Income tax (expense) benefit	(0.2)	0.1	0.7	0.1
Balance at end of period	(184.4)	16.6	(184.4)	16.6
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax	0.1	(0.1)	(0.2)
Balance at end of period attributable to Sirona Dental Systems, Inc.	(184.5)	16.7	(184.5)	16.7
Cumulated period computation
Balance at end of period	(184.7)	16.7	(184.7)	16.7
Cumulative translation adjustments
Balance at beginning of period	(230.8)	20.6	(85.6)	2.9
Current increase (decrease)	35.4	(9.9)	(110.1)	7.9
Income tax (expense) benefit	0	0	0	0
Balance at end of period	(195.4)	10.7	(195.4)	10.7
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax	0.1	(0.1)	(0.2)
Balance at end of period attributable to Sirona Dental Systems, Inc.	(195.5)	10.8	(195.5)	10.8
Cumulative translation adjustments | Cumulated period computation
Balance at end of period	(195.7)	10.8	(195.7)	10.8
Unrecognized elements of pension cost
Balance at beginning of period	10.9	6.5	13.2	6.4
Current increase (decrease)	0.4	(0.2)	(2.8)	(0.1)
Income tax (expense) benefit	(0.1)	0	0.8	0
Balance at end of period	11.2	6.3	11.2	6.3
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax	0	0	0
Balance at end of period attributable to Sirona Dental Systems, Inc.	11.2	6.3	11.2	6.3
Unrecognized elements of pension cost | Cumulated period computation
Balance at end of period	11.2	6.3	11.2	6.3
Net gain (loss) from hedging instruments
Balance at beginning of period	(0.3)	(0.5)	(0.4)	(0.7)
Current increase (decrease)	0.2	0	0.3	0.2
Income tax (expense) benefit	(0.1)	0.1	(0.1)	0.1
Balance at end of period	(0.2)	(0.4)	(0.2)	(0.4)
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax	0	0	0
Balance at end of period attributable to Sirona Dental Systems, Inc.	(0.2)	(0.4)	(0.2)	(0.4)
Net gain (loss) from hedging instruments | Cumulated period computation
Balance at end of period	$ (0.2)	$ (0.4)	$ (0.2)	$ (0.4)

Inventories, net (Details)

Inventories, net (Details) - USD ($) $ in Millions	Jun. 30, 2015	Sep. 30, 2014
Inventories, net [Abstract]
Finished goods	$ 98.7	$ 86.8
Work in progress	14.1	14.3
Raw materials	39	39.7
Inventory, gross	151.8	140.8
Inventory reserve	(19.4)	(17.4)
Inventories, net	$ 132.4	$ 123.4

Product Warranty (Details)

Product Warranty (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Changes in the product warranty accrual
Balance at beginning of the period	$ 6.7	$ 10	$ 7.6	$ 9.7
Accruals for warranties issued	8.1	5.2	17.7	15.7
Warranty settlements made	(7.6)	(6)	(17.2)	(16.4)
Translation adjustment	0.2	(0.1)	(0.7)	0.1
Balance at end of the period	$ 7.4	$ 9.1	$ 7.4	$ 9.1

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Jun. 30, 2015	Sep. 30, 2014
Assets
Cash Equivalents (money market funds)	$ 218.7	$ 211.2
Derivative Assets	0.7
Liabilities
Derivative Liabilities	(0.2)	(1.5)
Business Combination-related liabilities	(13)	(14.2)
Total	206.2	195.5
Quoted Prices in Active Markets for Identical Instruments (Level 1)
Assets
Cash Equivalents (money market funds)	218.7	211.2
Derivative Assets	0
Liabilities
Derivative Liabilities	0	0
Business Combination-related liabilities	0	0
Total	218.7	211.2
Significant Other Observable Inputs (Level 2) | Foreign exchange contracts
Assets
Cash Equivalents (money market funds)	0	0
Derivative Assets	0.7
Liabilities
Derivative Liabilities	(0.2)	(1.5)
Business Combination-related liabilities	0	0
Total	0.5	(1.5)
Significant Unobservable Inputs (Level 3)
Assets
Cash Equivalents (money market funds)	0	0
Derivative Assets	0
Liabilities
Derivative Liabilities	0	0
Business Combination-related liabilities	(13)	(14.2)
Total	$ (13)	$ (14.2)

Fair Value Measurements (Deta48

Fair Value Measurements (Details 2) - Jun. 30, 2015 - USD ($) $ in Millions	Total	Total
Fair Value Measurements [Abstract]
Income statement impact of the acquisition	$ (0.3)	$ 0.4
Changes in fair value of contingent consideration		$ (1.2)